Drugs That Prolong Qtc Interval

Concomitant use with KRAZATI is contraindicated.

Co-administration may increase risk of QTc interval prolongation. Avoid concomitant use; if unavoidable, monitor closely for QTc prolongation.

Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation due to risk of serious cardiac arrhythmias.

Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation due to risk of serious cardiac arrhythmias.

Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation due to risk of serious cardiac arrhythmias.

Increased risk of ventricular arrhythmias when used with beta-2 agonists. Use with caution.

Drugs that prolong QTc interval may potentiate cardiovascular effects. Use with extreme caution.

Additional QTc interval prolongation observed during combination treatment with SIRTURO. Monitor ECGs and discontinue if serious ventricular arrhythmia or QTc >500 ms occurs.

Concomitant use can cause additional QT prolongation.

May potentiate cardiovascular effects of formoterol with increased risk of ventricular arrhythmias. Use with extreme caution.

May potentiate cardiovascular effects and increase risk of ventricular arrhythmias. Use with extreme caution.

Co-administration may increase risk of QTc interval prolongation. Avoid concomitant use or monitor closely if unavoidable.

Use with extreme caution. May potentiate cardiovascular effects and increase risk of ventricular arrhythmias.

Concomitant use may result in greater QTc interval prolongation and adverse reactions including torsade de pointes, serious arrhythmias, and sudden death.

Increased risk of inducing ventricular arrhythmias when used concomitantly with hydroxychloroquine sulfate tablets.

Coadministration with drugs known to prolong QT interval should be avoided due to risk of QT prolongation. If unavoidable, monitor ECG.

Avoid concomitant use. Lonafarnib causes QTc prolongation; combined use may result in greater QTc interval increase and serious arrhythmias including Torsade de pointes and sudden death.

May potentiate cardiovascular effects of olodaterol and increase risk of ventricular arrhythmias. Use with extreme caution.

QT interval prolongation and ventricular arrhythmias can occur with coadministration. Avoid coadministration of oxaliplatin with medicinal products with known potential to prolong QT interval.

Concomitant use may add to QT effects and increase risk of cardiac arrhythmia. Avoid combination.

Concomitant use should be avoided as it may result in increased QTc interval and associated adverse reactions. If unavoidable, frequent monitoring for QTc prolongation is required.

QTc-prolonging drugs may potentiate cardiovascular effects and increase risk of ventricular arrhythmias. Use with extreme caution.

CABENUVA should be used with caution in combination with drugs with a known risk of Torsade de Pointes due to rilpivirine's potential to prolong QTc interval at elevated concentrations.

Limited information on potential pharmacodynamic interaction; higher RPV doses prolonged QTc interval. Consider alternative medications in patients taking drugs with known Torsade de Pointes risk.

QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration with other products with known potential to prolong QT/QTc interval.

Concurrent use of granisetron oral solution with drugs known to prolong QT interval and/or are arrhythmogenic may result in clinical consequences.

Use olanzapine and fluoxetine with caution with other QT-prolonging drugs.

Co-administration may have additive effects on QT interval prolongation; monitoring of QT interval effects at 21 days is recommended.

Sunitinib is associated with QTc interval prolongation. Monitor QT interval more frequently with concomitant QT-prolonging medications.

Limited information available on potential pharmacodynamic interaction between rilpivirine and drugs that prolong the QTc interval.

Effect of co-administration is unknown. Avoid concomitant use if feasible; if unavoidable, conduct periodic ECG monitoring.

The interaction potential with drugs that prolong QT interval is unknown; close and frequent electrocardiogram monitoring is advised if used concomitantly.